A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
Virginia Commonwealth University · University of Arizona · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
656
total citations
- FWCI
- 25.75
- Percentile
- 100%
- References
- 45
Citations per year
Authors
10- AJArun J. SanyalCorresponding
Virginia Commonwealth University
- TBThomas Boyer
University of Arizona
- GGGuadalupe García–Tsao
Yale University, VA Connecticut Healthcare System, Connecticut Health Foundation
- FRFrederick Regenstein
Tulane University
- LRLorenzo Rossaro
University of California Davis Medical Center
Topics & keywords
Topics
Keywords
- Terlipressin
- Hepatorenal syndrome
- Double blind
- Medicine
- Placebo
- Randomized controlled trial
- Internal medicine
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.